PPMX-T003
Phase 1Small molecule
PPMX-T003 is one of 76 small molecule programs targeting Polycythemia Vera. It is currently in Phase 1.
2
Indications
2
Total Trials
1
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Fludara
SanofiPhase 3
Rituxan
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Vepesid
AAvyxa
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Cellcept
RochePhase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Busulfex
Akero TherapeuticsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PPMX-T003. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- HHiroshima University Hospital